Regresar

Polimorfismo acetilador en el cancer de pulm6n

Abstract:

The acetylation phenotype was determined, by means of sulfamethazine measurement, in 87 patien ts (83 male) with con firmed bronchogenic carcinoma and in 93 healthy control patients (41 male) of equal ages. 48 patients and 54 controls were classified as being «slow acetylators» (Ch2n.s.) When the persons were individually analysed by phenotype, it was confirmed that the pa tients showed a significantly lower rate of acetylated sulfamethazine than the control group (p <0.02), owing to the poor acetylation of patients with small-cell lung cancer. This difference should be confirmed by more detailed pharmacokinetic studies before regarding i t as a possible interference of paraneoplasic type. The polymorphism acetylator cannot be considered a genetic marker related to the risk of having lung cancer.